|
重组人凝血因子 在中国血友病A患者的有效性及抑制物产生的观察 |
| |
formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy International KogenateFS Study Group［J］. Thromb Haemost ，2000，83: 811816.
[4] KREUZ W, ESCURIOLA ETTINGSHAUSEN C, FUNK M et al. Prevention of joint damage in hemophilic children with early prophylaxis［J］. Orthopade， 1999，28: 341346.
[5] YOSHIOKA A, SHIMA M, FUKUTAKE K, et al. Safety and efficacy of a new recombinant FⅧ formulated with sucrose (rFⅧFS) in patients with haemophilia A: a longterm, multicentre clinical study in Japan[J]. Haemophilia, 2001,7 (3);242249.
[6] YOSHIOKA A, FUKUTAKE K, et al. Clinical evaluation of recombinant factor VIII preparation (Kogenate) in previously treated patients with hemophilia A: descriptive metaanalysis of postmarketing study data［J］. Int J Hematol, 2006, 84(2):158165.
[7] 刘欣，吴竞生，孙萍，等. 基因重组人凝血因子Ⅷ在中国人血友病A患者中使用的研究［J］. 血栓与止血学, 2007,13(2):5759.
[8] MEEKS SL, JOSEPHSON CD, et al. Should hemophilia treaters switch to albuminfree recombinant factor VIII concentrates［J］. Curr Opin Hematol, 2006, 13(6):457461.
[9] SEREMETIS S, LUSHER JM, ABILDGAARD CF, et al. Human recombinant DNAderived antihaemophil上一页 [1] [2] [3] [4] [5] [6] [7] [8] 下一页
上一个医学论文： 白血病患者炎症因子 VEGF表达与易栓状态关系的研究
下一个医学论文： 出血性血小板病患者凝血酶受体GP Ib IX V复合物表达研究
|
|
|
|
|
|
|
您现在的位置： 绿色健康网 >> 医学论文 >> 内科论文 >> 正文